650 related articles for article (PubMed ID: 8768919)
21. The use of Health Care Financing Administration data for the development of a quality improvement project on the treatment of anemia.
Eggers PW; Greer J; Jencks S
Am J Kidney Dis; 1994 Aug; 24(2):247-54. PubMed ID: 8048432
[TBL] [Abstract][Full Text] [Related]
22. Medicare Program; End-Stage Renal Disease Prospective Payment System, Coverage and Payment for Renal Dialysis Services Furnished to Individuals With Acute Kidney Injury, End-Stage Renal Disease Quality Incentive Program, Durable Medical Equipment, Prosthetics, Orthotics and Supplies Competitive Bidding Program Bid Surety Bonds, State Licensure and Appeals Process for Breach of Contract Actions, Durable Medical Equipment, Prosthetics, Orthotics and Supplies Competitive Bidding Program and Fee Schedule Adjustments, Access to Care Issues for Durable Medical Equipment; and the Comprehensive End-Stage Renal Disease Care Model. Final rule.
Centers for Medicare & Medicaid Services (CMS), HHS
Fed Regist; 2016 Nov; 81(214):77834-969. PubMed ID: 27905888
[TBL] [Abstract][Full Text] [Related]
23. Recombinant human erythropoietin therapy for anemic cancer patients on combination chemotherapy.
Case DC; Bukowski RM; Carey RW; Fishkin EH; Henry DH; Jacobson RJ; Jones SE; Keller AM; Kugler JW; Nichols CR
J Natl Cancer Inst; 1993 May; 85(10):801-6. PubMed ID: 8487324
[TBL] [Abstract][Full Text] [Related]
24. Investigation of the efficacy of a biogeneric recombinant human erythropoietin alfa in the management of renal anemia in patients on hemodialysis: a multi-center clinical trial.
Beiraghdar F; Panahi Y; Einollahi B; Nemati E; Ghadiani MH; Sahebkar A; Maghsoudi N; Marzony ET
Clin Lab; 2012; 58(7-8):737-45. PubMed ID: 22997974
[TBL] [Abstract][Full Text] [Related]
25. Trends in erythropoietin therapy in the U.S. dialysis population: 1995 to 1998.
Kimmel PL; Greer JW; Milam RA; Thamer M
Semin Nephrol; 2000 Jul; 20(4):335-44. PubMed ID: 10928335
[TBL] [Abstract][Full Text] [Related]
26. Recombinant human erythropoietin versus placebo or no treatment for the anaemia of chronic kidney disease in people not requiring dialysis.
Cody JD; Hodson EM
Cochrane Database Syst Rev; 2016 Jan; 2016(1):CD003266. PubMed ID: 26790135
[TBL] [Abstract][Full Text] [Related]
27. A 6-month study of low-dose recombinant human erythropoietin alone and in combination with androgens for the treatment of anemia in chronic hemodialysis patients.
Gaughan WJ; Liss KA; Dunn SR; Mangold AM; Buhsmer JP; Michael B; Burke JF
Am J Kidney Dis; 1997 Oct; 30(4):495-500. PubMed ID: 9328363
[TBL] [Abstract][Full Text] [Related]
28. Early adoption of cyclosporine and recombinant human erythropoietin: clinical, economic, and policy issues with emergence of high-cost drugs.
Powe NR; Eggers PW; Johnson CB
Am J Kidney Dis; 1994 Jul; 24(1):33-41. PubMed ID: 8023822
[TBL] [Abstract][Full Text] [Related]
29. Survival benefit of recombinant human erythropoietin administration prior to onset of end-stage renal disease: variations across surrogates for quality of care and time.
Lu WX; Jones-Burton C; Zhan M; Salzberg DJ; Moore J; Fink JC
Nephron Clin Pract; 2005; 101(2):c79-86. PubMed ID: 15976508
[TBL] [Abstract][Full Text] [Related]
30. Treatment and survival differences in older Medicare patients with lung cancer as compared with those who are dually eligible for Medicare and Medicaid.
Bradley CJ; Dahman B; Given CW
J Clin Oncol; 2008 Nov; 26(31):5067-73. PubMed ID: 18794546
[TBL] [Abstract][Full Text] [Related]
31. The efficacy of erythropoietin in human immunodeficiency virus-infected end-stage renal disease patients treated by maintenance hemodialysis.
Shrivastava D; Rao TK; Sinert R; Khurana E; Lundin AP; Friedman EA
Am J Kidney Dis; 1995 Jun; 25(6):904-9. PubMed ID: 7771487
[TBL] [Abstract][Full Text] [Related]
32. Use of subcutaneous recombinant human erythropoietin in children undergoing continuous cycling peritoneal dialysis.
Sinai-Trieman L; Salusky IB; Fine RN
J Pediatr; 1989 Apr; 114(4 Pt 1):550-4. PubMed ID: 2926567
[TBL] [Abstract][Full Text] [Related]
33. Recombinant human erythropoietin therapy in children on dialysis.
Jabs K; Harmon WE
Adv Ren Replace Ther; 1996 Jan; 3(1):24-36. PubMed ID: 8620365
[TBL] [Abstract][Full Text] [Related]
34. Finding a rational approach to ESA therapy--for payers and patients.
Messana A
Nephrol News Issues; 2007 Sep; 21(10):54, 56. PubMed ID: 17918481
[No Abstract] [Full Text] [Related]
35. Treatment of the anemia of chronic renal failure with subcutaneous recombinant human erythropoietin.
Watson AJ; Gimenez LF; Cotton S; Walser M; Spivak JL
Am J Med; 1990 Oct; 89(4):432-5. PubMed ID: 2220877
[TBL] [Abstract][Full Text] [Related]
36. Recombinant human erythropoietin in the treatment of cancer and chemotherapy-induced anemia: results of double-blind and open-label follow-up studies.
Henry DH; Abels RI
Semin Oncol; 1994 Apr; 21(2 Suppl 3):21-8. PubMed ID: 8202722
[TBL] [Abstract][Full Text] [Related]
37. Effect of facility-level hemoglobin concentration on dialysis patient risk of transfusion.
Collins AJ; Monda KL; Molony JT; Li S; Gilbertson DT; Bradbury BD
Am J Kidney Dis; 2014 Jun; 63(6):997-1006. PubMed ID: 24315770
[TBL] [Abstract][Full Text] [Related]
38. Changes in anemia management and hemoglobin levels following revision of a bundling policy to incorporate recombinant human erythropoietin.
Hasegawa T; Bragg-Gresham JL; Pisoni RL; Robinson BM; Fukuhara S; Akiba T; Saito A; Kurokawa K; Akizawa T
Kidney Int; 2011 Feb; 79(3):340-6. PubMed ID: 20962740
[TBL] [Abstract][Full Text] [Related]
39. A study of the "crossover population": aged persons entitled to both Medicare and Medicaid.
McMillan A; Pine PL; Gornick M; Prihoda R
Health Care Financ Rev; 1983; 4(4):19-46. PubMed ID: 10309998
[TBL] [Abstract][Full Text] [Related]
40. Anemia management of adult hemodialysis patients in the US results: from the 1997 ESRD Core Indicators Project.
Frankenfield D; Johnson CA; Wish JB; Rocco MV; Madore F; Owen WF
Kidney Int; 2000 Feb; 57(2):578-89. PubMed ID: 10652035
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
